Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In silico pharmacogenetic approach: The natalizumab case study.

Toxicology and applied pharmacology - 1 Sept 2017

Cavaliere Francesca, Montanari Enrico, Emerson Andrew, Buschini Annamaria, Cozzini Pietro

Abstract excerpt

Natalizumab is a humanized monoclonal antibody to α4β1 integrin and is approved for the treatment of Multiple Sclerosis. In patients there is a great variation in drug response and there is much evidence that genetic contributors play an important role in defining an individual's susceptibility. Natalizumab binds to α4-residues Gln-152, Lys-201, Lys256, and these seem to be essential for its activity. Studies on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computer Simulation
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Algorithms

Share to Drug Resistance, Neoplasm

Share to Molecular Docking Simulation

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Protein Binding

Source

Identifiers

PMID: 28733203
DOI: 10.1016/j.taap.2017.07.011

Genes

ITGA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In silico pharmacogenetic approach: The natalizumab case study.PMID 28733203Read ↗

A computational approach to analyse the amino acid variants of GLB1 protein causing GM1 Gangliosidosis.Semantic proximity Read ↗

In-silico screening and microsecond molecular dynamics simulations to identify single point mutations that destabilize β-hexosaminidase A causing Tay-Sachs disease.Semantic proximity Read ↗

Insight into the modified Ibalizumab-human CD4 receptor interactions: using a computational binding free energy approach.Semantic proximity Read ↗

Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.Semantic proximity Read ↗

Pyrimethamine-based targeting of HEXA gene mutations in Tay-Sachs disease: a computational analysisSemantic proximity Read ↗

Molecular Dynamics: New Frontier in Personalized Medicine.Semantic proximity Read ↗

In silico prediction of ARB resistance: A first step in creating personalized ARB therapySemantic proximity Read ↗

Molecular dynamics simulations involving different β-propeller mutations reported in Swiss and French patients correlate with their disease phenotypes.Semantic proximity Read ↗

Association analysis of Vascular Endothelial Growth Factor-A (VEGF-A) polymorphism in rheumatoid arthritis using computational approaches.Semantic proximity Read ↗

Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple SclerosisSemantic proximity Read ↗

SNP analysis of Rac1 For personalized ligand interaction.Semantic proximity Read ↗

In silico prediction of ARB resistance: A first step in creating personalized ARB therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.